Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48, Toripalimab, and Radiotherapy for Bladder Preservation in MIBC
NCT05979740Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by Renji Hospital. Primary endpoint: Safety at 28 days. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05979740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979740.